Arcus Biosciences Stock Buy Hold or Sell Recommendation
| RCUS Stock | USD 15.94 0.50 3.24% |
Given the investment horizon of 90 days and your bold attitude towards risk, our recommendation regarding Arcus Biosciences is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Arcus Biosciences given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Arcus Biosciences, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Arcus Biosciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide. Note, we conduct extensive research on individual companies such as Arcus and provide practical buy, sell, or hold advice based on investors' constraints. Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Arcus |
Execute Arcus Biosciences Buy or Sell Advice
The Arcus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Arcus Biosciences. Macroaxis does not own or have any residual interests in Arcus Biosciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Arcus Biosciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Arcus Biosciences Trading Alerts and Improvement Suggestions
| Arcus Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 117 M. Net Loss for the year was (307 M) with loss before overhead, payroll, taxes, and interest of (176 M). | |
| Arcus Biosciences currently holds about 1.05 B in cash with (306 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48. | |
| Arcus Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Arcus Biosciences, Inc.s Price Is Right But Growth Is Lacking |
Arcus Biosciences Returns Distribution Density
The distribution of Arcus Biosciences' historical returns is an attempt to chart the uncertainty of Arcus Biosciences' future price movements. The chart of the probability distribution of Arcus Biosciences daily returns describes the distribution of returns around its average expected value. We use Arcus Biosciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Arcus Biosciences returns is essential to provide solid investment advice for Arcus Biosciences.
| Mean Return | -0.06 | Value At Risk | -5.85 | Potential Upside | 7.43 | Standard Deviation | 3.55 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Arcus Biosciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Arcus Stock Institutional Investors
The Arcus Biosciences' institutional investors refer to entities that pool money to purchase Arcus Biosciences' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Parkman Healthcare Partners Llc | 2024-09-30 | 1 M | Bnp Paribas Investment Partners Sa | 2024-09-30 | 931 K | Decheng Capital Llc | 2024-09-30 | 869.8 K | Ikarian Capital, Llc | 2024-09-30 | 744 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 714.5 K | Goldman Sachs Group Inc | 2024-09-30 | 703.3 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 673.8 K | Suvretta Capital Management, Llc | 2024-09-30 | 663.6 K | Blackrock Inc | 2024-06-30 | 9.8 M | Vanguard Group Inc | 2024-09-30 | 5.5 M |
Arcus Biosciences Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 61.1M | (431.3M) | (28.8M) | (413M) | 213M | 223.7M | |
| Change In Cash | (13.1M) | 115.5M | (22.7M) | 58M | (79M) | (75.1M) | |
| Free Cash Flow | (75.4M) | 108.1M | (282.2M) | 426M | (330M) | (313.5M) | |
| Depreciation | 3.6M | 4.2M | 3.8M | 6M | 8M | 4.6M | |
| Other Non Cash Items | (1.4M) | (46K) | 3.5M | 11M | (9M) | (8.6M) | |
| Capital Expenditures | 1.9M | 3.1M | 26.1M | 12M | 24M | 25.2M | |
| Net Income | (84.7M) | (122.9M) | 52.8M | (267M) | (307M) | (291.7M) | |
| End Period Cash Flow | 58.1M | 173.6M | 150.9M | 209M | 130M | 131.5M | |
| Change To Netincome | 10.2M | 21.8M | 54.5M | 76M | 87.4M | 91.8M |
Arcus Biosciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Arcus Biosciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Arcus Biosciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Arcus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | 1.76 | |
σ | Overall volatility | 3.58 | |
Ir | Information ratio | -0.05 |
Arcus Biosciences Volatility Alert
Arcus Biosciences exhibits very low volatility with skewness of 0.16 and kurtosis of 0.87. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arcus Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arcus Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Arcus Biosciences Fundamentals Vs Peers
Comparing Arcus Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Arcus Biosciences' direct or indirect competition across all of the common fundamentals between Arcus Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Arcus Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Arcus Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Arcus Biosciences to competition |
| Fundamentals | Arcus Biosciences | Peer Average |
| Return On Equity | -0.5 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Profit Margin | (1.03) % | (1.27) % |
| Operating Margin | (2.19) % | (5.51) % |
| Current Valuation | 381.94 M | 16.62 B |
| Shares Outstanding | 91.51 M | 571.82 M |
| Shares Owned By Insiders | 40.00 % | 10.09 % |
| Shares Owned By Institutions | 60.05 % | 39.21 % |
| Number Of Shares Shorted | 7.57 M | 4.71 M |
| Price To Earning | 27.69 X | 28.72 X |
| Price To Book | 2.50 X | 9.51 X |
| Price To Sales | 5.55 X | 11.42 X |
| Revenue | 117 M | 9.43 B |
| Gross Profit | (176 M) | 27.38 B |
| EBITDA | (283 M) | 3.9 B |
| Net Income | (307 M) | 570.98 M |
| Cash And Equivalents | 1.05 B | 2.7 B |
| Cash Per Share | 14.48 X | 5.01 X |
| Total Debt | 11 M | 5.32 B |
| Debt To Equity | 0.17 % | 48.70 % |
| Current Ratio | 6.22 X | 2.16 X |
| Book Value Per Share | 6.17 X | 1.93 K |
| Cash Flow From Operations | (306 M) | 971.22 M |
| Short Ratio | 8.48 X | 4.00 X |
| Earnings Per Share | (3.19) X | 3.12 X |
| Target Price | 33.2 | |
| Number Of Employees | 577 | 18.84 K |
| Beta | 0.89 | -0.15 |
| Market Capitalization | 1.46 B | 19.03 B |
| Total Asset | 1.09 B | 29.47 B |
| Retained Earnings | (849 M) | 9.33 B |
| Working Capital | 647 M | 1.48 B |
| Net Asset | 1.09 B |
Note: Acquisition by Kathryn Falberg of 8400 shares of Arcus Biosciences subject to Rule 16b-3 [view details]
Arcus Biosciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Arcus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Arcus Biosciences Buy or Sell Advice
When is the right time to buy or sell Arcus Biosciences? Buying financial instruments such as Arcus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Arcus Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks Thematic Idea Now
Banks
Large and small money and credit banks and credit services. The Banks theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.